While U.S. patients are seeing their finances blown up by skyrocketing prescription drug prices, the members of Congress continue to wring their hands, ponder responses — and do nothing. The Federal Trade Commission, though, has at least launched an investigation of one part of Big Pharma to see if pharmacy benefit managers, the industry middlemen known as PBMs, jack up prices for patients.
Those footing the bill for drugs have plenty of reason for outrage, a trio of researchers from Brigham and Women’s Hospital in Boston have reported.
Their findings, published in the Journal of the American Medical Association, show just how stark Big Pharma’s recent push for profits has been. As the researchers wrote in a New York Times Op-Ed, calling for congressional action to lower drug prices, based on their study: